American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, SchĂĽnemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-SchĂĽnemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, SchĂĽnemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, PMCID: PMC11950770, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized controlled trialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled trialsMcMaster University
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply